Optimer Pharmaceuticals, drug development partner of Asia’s largest biotechnology company Biocon, has received a US patent for fidaxomicin, an antibiotic used in the treatment of clostridium difficile infection (CDI). The patent will be extended up to March 2027.
CDI is an illness caused by an infection that can result in severe diarrhoea and in serious cases, death. Biocon will manufacture the active pharmaceutical ingredient (API) for fidaxomicin.
Biocon produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies. The drug major also produces mycophenolate mofetil, sirolimus and tacrolimus.
No comments:
Post a Comment